Differentiation of angiogenic burden in human cancer xenografts using a perfusion-type optical contrast agent (SIDAG)

Table 1 Summary of results for all tumour xenografts

Tumour model	CNR calculated by FRI (AU)^a	FMT (nmol/l)	VVF (%)^b	BVPD (BVPs/mm²)
MDA-MB435: melanoma	389 ± 72 (n = 10)	229 ± 90 (n = 4)	3.58 ± 0.9 (n = 4)	399 ± 36 (n = 6)
HT1080: fibrosarcoma	232 ± 99 (n = 11)	92 ± 65 (n = 5)	1.9 ± 0.7 (n = 4)	128 ± 38 (n = 6)
MCF7: adenocarcinoma	185 ± 57 (n = 9)	65 ± 50 (n = 6)	0.75 ± 0.5 (n = 4)	59 ± 10 (n = 6)
DU4475: adenocarcinoma	167 ± 79 (n = 13)	49 ± 22 (n = 4)	0.8 ± 0.5 (n = 4)	78 ± 16 (n = 6)

Data are expressed as mean ± standard deviation. Note that the data generated by fluorescence imaging technologies (FRI, FMT) correlate well with in in vivo (VVF) and ex vivo (BVDP) surrogate markers of tumour angiogenesis. ^aCalculated 24 hours after intravenous injection of SIDAG. ^bMeasured using magnetic resonance imaging. AU, arbitrary units; BVP, blood vessel profile; BVPD: blood vessel profiles density; FMT, fluorescence-mediated tomography; FRI, fluorescence reflectance imaging; VVF, vascular volume fraction.

ISSN: 1465-542X